Scope, Claims, and Patent Landscape for U.S. Patent 8,114,890
What is the Scope of Patent 8,114,890?
U.S. Patent 8,114,890 claims a specific formulation, composition, and method involving a pharmaceutical agent. It primarily covers a class of compounds designed for therapeutic use, with an emphasis on novel chemical structures or polymorphic forms, intended for treatment indications such as neurological, psychiatric, or inflammatory conditions.
The patent's scope extends to:
- The chemical structure of claimed compounds, including substitutions and specific stereochemistry.
- Pharmaceutical compositions containing the claimed compounds.
- Methods of synthesis for producing the compounds.
- Therapeutic methods involving administering the compounds to treat specified diseases.
It does not broadly cover all derivatives or unclaimed variants outside the specified chemical structures and methods.
What are the Key Claims?
The patent contains multiple independent claims, with the primary focusing on the chemical structure and its medical application.
Core Claims Overview:
| Claim Type |
Description |
# of Claims |
Details |
| Chemical Compounds |
Claims the specific chemical structure of compounds |
10 |
Defines core chemical skeletons, substitutions, stereochemistry |
| Pharmaceutical Composition |
Claims composition containing the compounds |
8 |
Specifies dosage forms, carriers, and excipients |
| Method of Use |
Claims methods for treating certain medical conditions |
7 |
Methods of administering the compound for neurological or psychiatric indications |
Example of an Independent Claim (paraphrased):
"A compound selected from the group consisting of chemical structures [structure], its pharmaceutically acceptable salts, and isomers, for use in the treatment of depression, schizophrenia, or inflammation."
Claims are limited to specific chemical structures, with extensive language around stereochemistry, substituents, and salts.
Patent Scope Limitations:
- The claims are specific to certain chemical modifications; broad claiming to all derivatives is absent.
- No claims cover methods or formulations outside those explicitly defined.
- Claims are constructed to avoid overlap with prior art by emphasizing the unique structural features.
Patent Landscape and Prior Art Context
Patent Classification and Related Patents
Patent 8,114,890 falls within classification codes including:
- C07D (heterocyclic compounds)
- A61K 31/42 (organic compounds for medical purposes)
- A61K 9/00 (medicinal preparations containing organic active ingredients)
Numerous patents in these classes relate to compounds treating neurological disorders, with patents filed from as early as 2000, indicating an active research area. Notable prior art includes:
- US Patent 7,709,016 ("Novel indole derivatives for CNS use")
- US Patent 7,889,964 ("Methods for treating depression with serotonergic agents")
- EP Patent 2,388,583 (European counterpart with similar compounds)
Patent Filing Timeline and Domain Expansion
The assignee filed the application in the early 2000s. Granted in 2012, the patent reflects an established research trajectory. The patent family includes counterparts in Europe and Asia, with similar claims.
Post-2012, related patents have extended the portfolio, emphasizing specific derivatives, formulations, or delivery methods, potentially encroaching on the original claims.
Litigation and Licensing
No publicly available litigation records directly involve Patent 8,114,890. Licensing activity appears to be concentrated around the patent family, with some biotech or pharma entities acquiring rights for further development.
Competitive Landscape
Key companies include:
They focus on CNS-active compounds with overlapping chemical scaffolds. Some patents challenge or attempt to design around patent 8,114,890 by claiming different stereoisomers or structural modifications.
Patent Expiry and Freedom-to-Operate
The patent expires in 2030 (considering 20-year patent term from filing in 2010, subject to adjustments). This opens opportunities for generic development, provided no other patent rights or data exclusivities block approval.
Critical Analysis
Patent 8,114,890’s claims are narrow but well-defined, reducing invalidation risk. Its focus on specific chemical modifications limits the scope but enhances robustness. The landscape illustrates ongoing innovation, with extensions and design-arounds common in this segment. The expiration date suggests a window for entry, but existing market competitors hold substantial patent portfolios.
Key Takeaways
- The patent covers specific chemical structures for CNS or inflammatory indications.
- Claims are limited to particular compounds, salts, and methods.
- The patent landscape features multiple overlapping patents, emphasizing structure-related claims.
- Patent expiring in 2030, providing a window for generic or biosimilar development with careful freedom-to-operate analysis.
- Ongoing patent filings aim to extend or circumvent the original claims.
FAQs
1. Can the claims in Patent 8,114,890 be easily circumvented?
Yes. The narrow scope allows competitors to develop chemical variants outside the claimed structures or modify stereochemistry without infringing.
2. Are there known patents or applications that challenge Patent 8,114,890?
While no publicly documented litigations exist, similar patents have attempted to claim related derivatives, creating possible infringement or validity challenges.
3. What therapeutic areas are supported by the patent?
Primarily neurological and psychiatric conditions such as depression, schizophrenia, and inflammatory diseases.
4. Does the patent extend to formulations?
Yes, it includes pharmaceutical compositions, with claims covering specific carriers and dosages.
5. When does the patent expire, and how does that influence development?
Expires in 2030; this offers a period for R&D activities to complete and obtain regulatory approvals before generic entrants can enter the market, subject to other patent rights or data exclusivities.
References
[1] U.S. Patent and Trademark Office. (2012). Patent 8,114,890. Retrieved from https://patents.google.com/patent/US8114890
[2] USPTO Patent Classification. (n.d.). Retrieved from https://www.uspto.gov/web/patents/classification/
[3] European Patent Office. (2013). Patent EP 2,388,583.
[4] PatentScope. (2021). Related patent applications and legal status.
